Fry Simon's most recent trade in Conduit Pharmaceuticals Inc was a trade of 35,000 Common Stock done . Disclosure was reported to the exchange on Aug. 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Conduit Pharmaceuticals Inc | Simon Fry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2025 | 35,000 | 36,956 | - | 0 | Common Stock | |
| Conduit Pharmaceuticals Inc | Simon Fry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2025 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Conduit Pharmaceuticals Inc | Simon Fry | Director | Grant, award, or other acquisition of securities at price $ 0.89 per share. | 30 Mar 2025 | 29,354 | 31,354 | - | 0.9 | 26,125 | Common Stock |
| Conduit Pharmaceuticals Inc | Fry Simon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 420,000 | 420,000 | - | - | Stock Option (Right to Buy) |